Loading
PP
PhaseBio Pharmaceuticals Inc Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest was filed 19 Aug 2021.
PhaseBio Pharmaceuticals Inc: what insiders have been doing
Every trade that managers of PhaseBio Pharmaceuticals Inc disclose to SEC (Form 4) is tracked on this page. The company sits in the Healthcare & Pharma sector. The past year has been quiet: not a single insider filing for PhaseBio Pharmaceuticals Inc. The previous disclosure was published on 19 May 2023.
Looking back to 2021, when coverage begins, insiders filed 2 purchases and 1 sale.
In the same sector, recent insider purchases at Anixa Biosciences Inc and Vivos Inc also feature in our signals. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Insider Decl.
33
Thresholds
n/a
Buy Volume
€33,529
2 ops. · all time
Sell Volume
€263,219
1 ops. · all time
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2021FY ended December 2021 · cache
Income statement
RevenueUS$9.3M
Net income-US$112.9M-1210.1% margin
Last declaration on 19 May 2023
Declarations33 total
3,750 sharesCommon StockSEC:0001169245-23-000030:0
3,750 sharesCommon StockSEC:0001169245-23-000032:0
3,750 sharesCommon StockSEC:0001169245-23-000027:0
2,538 sharesCommon StockSEC:0001169245-23-000031:0
3,750 sharesCommon StockSEC:0001169245-23-000028:0
3,750 sharesCommon StockSEC:0001169245-23-000029:0
3,750 sharesCommon StockSEC:0001169245-23-000033:0
1,784,109 shares@ US$0.147100.0% of flowCommon StockSEC:0001209191-22-054647:0
20,000 shares@ US$0.6813100.0% of flowCommon StockSEC:0001169245-22-000075:0
10,918 shares@ US$0.681310.3% of flowCommon StockSEC:0001169245-22-000078:0
6,026 shares@ US$0.681312.1% of flowCommon StockSEC:0001169245-22-000074:0
11,248 shares@ US$0.681327.7% of flowCommon StockSEC:0001169245-22-000077:0
4,831 shares@ US$0.681337.3% of flowCommon StockSEC:0001169245-22-000076:0
10,917 shares@ US$0.681323.3% of flowCommon StockSEC:0001169245-22-000079:0
5,623 shares@ US$2.0114.5% of flowCommon StockSEC:0001169245-21-000129:0
2,017 shares@ US$2.0111.1% of flowCommon StockSEC:0001169245-21-000127:0
1,545 shares@ US$2.0132.8% of flowCommon StockSEC:0001169245-21-000126:0
5,766 shares@ US$2.0139.0% of flowCommon StockSEC:0001169245-21-000125:0
2,559 shares@ US$2.0115.0% of flowCommon StockSEC:0001169245-21-000128:0
24,860 shares@ US$2.2686.0% of flowCommon StockSEC:0001169245-21-000106:0
7,500 shares@ US$1.6833.8% of flowCommon StockSEC:0001169245-21-000103:0
20,000 shares@ US$1.2431.2% of flowCommon StockSEC:0001169245-21-000104:0
20,000 shares@ US$1.2430.8% of flowCommon StockSEC:0001169245-21-000085:0
3,000 shares@ US$3.0814.0% of flowCommon StockSEC:0001169245-21-000083:0
Canonical exit: 16 Nov 2021 (T+90)
10,000 shares@ US$3.00100.0% of flowCommon StockSEC:0001169245-21-000080:0
Canonical exit: 16 Nov 2021 (T+90)
25 of 33 declarations
About PhaseBio Pharmaceuticals Inc
PhaseBio Pharmaceuticals Inc. is a U.S.-based biopharmaceutical company historically focused on developing therapies for cardiovascular and cardiopulmonary diseases. Its principal executive offices were in Malvern, Pennsylvania, with an additional operational presence in San Diego, California. The company was founded as a clinical-stage biotech business with a mission to address serious diseases where treatment options remained limited. From a market perspective, PhaseBio was associated with the NASDAQ market in the United States before its share listing was suspended in the context of financial distress and the Chapter 11 process the company initiated in October 2022.
PhaseBio’s core scientific asset was its proprietary elastin-like polypeptide, or ELP, platform. The platform was designed to improve the pharmacokinetics of proteins and peptides by extending half-life and supporting less frequent dosing. This technology underpinned the company’s research strategy and gave it a differentiated angle versus more conventional biotech approaches. The best-known program in its pipeline was bentracimab, also known as PB2452, a reversal agent intended to rapidly and sustainably neutralize the antiplatelet effects of ticagrelor in patients experiencing major bleeding or requiring urgent surgery or invasive procedures. For a long time, bentracimab represented the company’s lead value driver and the program most closely watched by investors.
Read moreShow less
In competitive terms, PhaseBio operated in a narrow, high-need specialty area at the intersection of cardiology, acute care, and hemostasis. Its key competitive rationale was the potential lack of a like-for-like alternative for ticagrelor reversal, which made the asset clinically important for hospitals, emergency physicians, and procedural teams. The company also pursued external value creation through partnerships, including a licensing agreement with Alfasigma for commercialization rights in certain non-U.S. markets, highlighting an attempt to monetize the asset beyond its own commercial infrastructure.
Geographically, PhaseBio was primarily U.S.-centered, with research, management, and corporate functions based in the United States, while its commercialization strategy relied in part on international partners. Recent milestones that matter to investors include the Chapter 11 filing in October 2022, the loss of ongoing NASDAQ listing continuity, and subsequent disclosures tied to the restructuring and transfer of assets. For equity analysts, PhaseBio should therefore be viewed as a highly specialized clinical-stage biotechnology company whose investment case depended largely on a small number of programs and on the outcome of restructuring and asset disposition events in the United States.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
